Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2020

July 2020 | 30 pages | ID: EEAF30BF714EN
Global Markets Direct

Abstracts

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Elephantiasis - Pipeline Review, H2 2020, provides an overview of the Elephantiasis (Infectious Disease) pipeline landscape.
Elephantiasis commonly known as Lymphatic filariasis occurs when filarial parasites are transmitted to humans through mosquitoes. Infection is usually acquired in childhood causing hidden damage to the lymphatic system. Lymphatic filariasis is caused by infection with parasites classified as nematodes (roundworms) of the family Filariodidea. Symptoms include swelling, shaking chills, sweating, headaches, and vomiting. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Elephantiasis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Elephantiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Elephantiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Elephantiasis (Lymphatic Filariasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Elephantiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Elephantiasis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Elephantiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Elephantiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Elephantiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Elephantiasis (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Elephantiasis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Elephantiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Elephantiasis (Lymphatic Filariasis) - Overview
Elephantiasis (Lymphatic Filariasis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Elephantiasis (Lymphatic Filariasis) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Elephantiasis (Lymphatic Filariasis) - Companies Involved in Therapeutics Development
AbbVie Inc
Eisai Co Ltd
Medicines Development Ltd
Pai Life Sciences Inc
Elephantiasis (Lymphatic Filariasis) - Drug Profiles
ABBV-4083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AWZ-1066S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filariasis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lymphatic filariasis (multivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lymphatic filariasis (multivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
moxidectin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Elephantiasis (Lymphatic Filariasis) - Dormant Projects
Elephantiasis (Lymphatic Filariasis) - Product Development Milestones
Featured News & Press Releases
Jan 08, 2019: New anti-Wolbachia drug with potential to treat onchocerciasis and lymphatic filariasis
Sep 14, 2018: ?1.5M to develop candidate drug to treat onchocerciasis and lymphatic filariasis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Elephantiasis (Lymphatic Filariasis) - Pipeline by AbbVie Inc, H2 2020
Elephantiasis (Lymphatic Filariasis) - Pipeline by Eisai Co Ltd, H2 2020
Elephantiasis (Lymphatic Filariasis) - Pipeline by Medicines Development Ltd, H2 2020
Elephantiasis (Lymphatic Filariasis) - Pipeline by Pai Life Sciences Inc, H2 2020
Elephantiasis (Lymphatic Filariasis) - Dormant Projects, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

AbbVie Inc
Eisai Co Ltd
Medicines Development Ltd
Pai Life Sciences Inc